Back to Search
Start Over
Insulin resistance and associated factors among HIV-infected patients in sub-Saharan Africa: a cross sectional study from Cameroon.
- Source :
- Lipids in Health & Disease; 8/10/2017, Vol. 16, p1-7, 7p, 3 Charts
- Publication Year :
- 2017
-
Abstract
- Background: Little is known on the magnitude and correlates of insulin resistance in HIV-infected people in Africa. We determined the prevalence of insulin resistance and investigated associated factors in HIV-infected adult Cameroonians. Methods: We conducted a cross-sectional study at the Yaoundé Central Hospital, Cameroon; during which we enrolled HIV-infected people aged 30 to 74 years with no previous history of cardiovascular disease. An homeostatic model assessment of insulin resistance (HOMA-IR) like index served to assess insulin sensitivity with insulin resistance defined by values of 2.1 or higher. Results: We included 452 patients (20% men). Their mean age was 44.4 ± 9.8 years and 88.5% of them were on antiretroviral therapy (93.3% on first line regimen including Zidovudine, lamivudine and Efavirenz/Nevirapine). Of all participants, 28.5% were overweight, 19.5% had obesity and 2.0% had diabetes. The prevalence of insulin resistance was 47.3% without any difference between patients on ART and those ART-naïve (48.5% vs. 38.5%; p = 0.480). Obesity was the only factor independently associated with insulin resistance (adjusted odds ratio: 2.28; 95% confidence interval: 1.10-4.72). Conclusion: Insulin resistance is present in nearly half of HIV-infected patients in Cameroon despite a low prevalence rate of diabetes, and is associated with obesity. [ABSTRACT FROM AUTHOR]
- Subjects :
- INSULIN resistance
OBESITY
HIV-positive persons
CAMEROONIANS
PUBLIC health
HEALTH
Subjects
Details
- Language :
- English
- ISSN :
- 1476511X
- Volume :
- 16
- Database :
- Complementary Index
- Journal :
- Lipids in Health & Disease
- Publication Type :
- Academic Journal
- Accession number :
- 124614741
- Full Text :
- https://doi.org/10.1186/s12944-017-0543-1